Roku Explores Sale Options as Interest Grows in Streaming and Ad Business 
Asian Currencies Steady as BOJ Raises Rates and Markets Await Fed Decision 
Australia’s Atlas Arteria Rejects IFM Global’s Increased A$7.4 Billion Takeover Offer 
Gold Prices Surge Above $4,300 as US-Iran Peace Deal Weakens Dollar and Oil 
OpenAI's $34B Spending Pushes AI Market Leadership Ahead of IPO 
Lazard Challenges Centerview for Role in Venezuela’s Massive Debt Restructuring 
ByteDance Eyes Iluvatar, Baidu AI Chips Amid China’s AI Push 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
North Korea Reports Industrial Output at 105% of Target Following Party Congress 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
German Auto Suppliers Turn Bearish as Investment and Jobs Shift Overseas 
AI Memory Boom Sparks Global Chip Supply Crunch 
UK Banks Report Surge in APP Fraud Losses as Pressure Mounts on Meta and Tech Platforms 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Wall Street Surges as US-Iran Deal Eases Oil Price and Inflation Concerns 
SpaceX Stock Soars After Historic IPO, Reaches $2.5 Trillion Market Value 
Sigma Healthcare Shares Jump After Exiting Boots Acquisition Process 
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
